Literature DB >> 32513794

In Vitro Activities of Eravacycline and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas.

Ken B Waites1, Donna M Crabb2, Li Xiao3, Lynn B Duffy2, Sixto M Leal2.   

Abstract

We performed in vitro susceptibility testing for eravacycline in comparison to 4 other antimicrobials against 10 Mycoplasma genitalium, 40 Mycoplasma hominis, 44 Mycoplasma pneumoniae, 20 Ureaplasma parvum, and 20 Ureaplasma urealyticum isolates. All eravacycline MICs were ≤0.25 μg/ml, except that for one isolate of M. genitalium, for which the MIC was 2 μg/ml. Eravacycline was markedly more potent than tetracycline, azithromycin, moxifloxacin, and clindamycin against all isolates tested, which included 37 macrolide, tetracycline, and/or fluoroquinolone-resistant organisms.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  eravacycline; mycoplasma; pneumonia; ureaplasma; urogenital infection

Mesh：

Substances：

Year:  2020        PMID： 32513794      PMCID： PMC7526834          DOI： 10.1128/AAC.00698-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus.

Authors:  Amit Kaushik; Nicole C Ammerman; Olumide Martins; Nicole M Parrish; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

Review 2.  Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis.

Authors:  Rebecca Lis; Ali Rowhani-Rahbar; Lisa E Manhart
Journal:  Clin Infect Dis       Date:  2015-04-21       Impact factor: 9.079

3.  Macrolide-Resistant Mycoplasma pneumoniae in the United States as Determined from a National Surveillance Program.

Authors:  K B Waites; A Ratliff; D M Crabb; L Xiao; X Qin; R Selvarangan; Y-W Tang; X Zheng; J Dien Bard; T Hong; M Prichard; E Brooks; S Dallas; L Duffy; E Mixon; K B Fowler; T P Atkinson
Journal:  J Clin Microbiol       Date:  2019-10-23       Impact factor: 5.948

4.  Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

5.  Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic.

Authors:  Trudy H Grossman; Agata L Starosta; Corey Fyfe; William O'Brien; David M Rothstein; Aleksandra Mikolajka; Daniel N Wilson; Joyce A Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

6.  In Vitro Activities of Omadacycline (PTK 0796) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Yang Liu; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

Review 7.  Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.

Authors:  George G Zhanel; Jenine Esquivel; Sheryl Zelenitsky; Courtney K Lawrence; Heather J Adam; Alyssa Golden; Rachel Hink; Liam Berry; Frank Schweizer; Michael A Zhanel; Denice Bay; Philippe R S Lagacé-Wiens; Andrew J Walkty; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2020-02       Impact factor: 9.546

8.  Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens.

Authors:  J A Sutcliffe; W O'Brien; C Fyfe; T H Grossman
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

9.  Fluorocycline TP-271 Is Potent against Complicated Community-Acquired Bacterial Pneumonia Pathogens.

Authors:  Trudy H Grossman; Corey Fyfe; William O'Brien; Meredith Hackel; Mary Beth Minyard; Ken B Waites; Jacques Dubois; Timothy M Murphy; Andrew M Slee; William J Weiss; Joyce A Sutcliffe
Journal:  mSphere       Date:  2017-02-22       Impact factor: 4.389

10.  Overexpression of OqxAB and MacAB efflux pumps contributes to eravacycline resistance and heteroresistance in clinical isolates of Klebsiella pneumoniae.

Authors:  Jin-Xin Zheng; Zhi-Wei Lin; Xiang Sun; Wei-Hong Lin; Zhong Chen; Yang Wu; Guo-Bin Qi; Qi-Wen Deng; Di Qu; Zhi-Jian Yu
Journal:  Emerg Microbes Infect       Date:  2018-08-01       Impact factor: 7.163
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.